Loading…
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $419M | $79M | $49M | $73M | 18.9% | 20.0% | 14.5% |
| 2024 | $349M | $65M | $42M | $65M | 22.0% | 8.5% | -27.2% |
| 2023 | $321M | $41M | $58M | $25M | 40.8% | 20.0% | - |
| 2022 | $268M | $-11M | $-30M | $-19M | 167.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 267.84 | 321.48 | 348.88 | 418.63 |
| Cost Of Revenue | 48.32 | 54.63 | 60.07 | 73.01 |
| Gross Profit | 219.53 | 266.84 | 288.81 | 345.62 |
| Operating Expense | 234.25 | 229.73 | 229.50 | 281.73 |
| Operating Income | -14.73 | 37.12 | 59.31 | 63.89 |
| EBITDA | -10.69 | 40.54 | 65.35 | 78.77 |
| EBIT | -14.73 | 37.12 | 59.31 | 63.89 |
| Pretax Income | -19.75 | 30.63 | 57.29 | 66.26 |
| Tax Provision | 0.21 | -36.81 | 15.30 | 17.68 |
| Net Income | -30.20 | 58.23 | 42.42 | 48.58 |
| Net Income Common Stockholders | -36.78 | 46.59 | 42.42 | 48.58 |
| Total Expenses | 282.57 | 284.36 | 289.57 | 354.74 |
| Interest Expense | 5.02 | 6.46 | 1.01 | 0 |
| Research And Development | 12.70 | 12.66 | 12.34 | 15.10 |
| Selling General And Administration | 208.67 | 211.12 | 225.09 | 266.19 |
| Normalized EBITDA | -10.69 | 40.54 | 65.80 | 78.77 |
| Normalized Income | -19.95 | 67.44 | 42.32 | 48.58 |
| Basic EPS | -0.33 | 0.40 | 0.29 | 0.33 |
| Diluted EPS | -0.33 | 0.37 | 0.28 | 0.32 |
| Tax Effect Of Unusual Items | 0 | 0 | -0.12 | 0 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.27 | 0.27 |
| Total Unusual Items | 0 | 0 | -0.45 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -0.45 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -19.95 | 67.44 | 42 | 48.58 |
| Reconciled Depreciation | 4.05 | 3.43 | 6.04 | 14.88 |
| Reconciled Cost Of Revenue | 44.97 | 51.97 | 54.80 | 58.57 |
| Net Interest Income | -5.02 | -6.46 | -1.01 | 2.93 |
| Net Income From Continuing And Discontinued Operation | -30.20 | 58.23 | 42.42 | 48.58 |
| Total Operating Income As Reported | -14.73 | 37.12 | 58.87 | 63.89 |
| Diluted Average Shares | 112.91 | 145.96 | 149.05 | 149.72 |
| Basic Average Shares | 112.91 | 116.50 | 146.98 | 147.79 |
| Diluted NI Availto Com Stockholders | -36.78 | 46.59 | 42.42 | 48.58 |
| Otherunder Preferred Stock Dividend | 0 | 4.89 | 0 | 0 |
| Preferred Stock Dividends | 6.58 | 6.75 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -30.20 | 58.23 | 42.42 | 48.58 |
| Net Income Discontinuous Operations | -10.24 | -9.21 | 0.42 | 0 |
| Net Income Continuous Operations | -19.95 | 67.44 | 42 | 48.58 |
| Other Income Expense | 0 | -0.03 | -1.01 | -0.56 |
| Other Non Operating Income Expenses | 0 | -0.03 | -0.56 | -0.56 |
| Special Income Charges | 0 | 0 | -0.45 | 0 |
| Impairment Of Capital Assets | 0 | 0 | 0.45 | 0 |
| Net Non Operating Interest Income Expense | -5.02 | -6.46 | -1.01 | 2.93 |
| Total Other Finance Cost | 0 | 6.46 | 1.01 | -2.93 |
| Interest Expense Non Operating | 5.02 | 6.46 | 1.01 | 0 |
| Other Operating Expenses | 12.18 | 5.18 | -8.70 | 0 |
| Depreciation Amortization Depletion Income Statement | 0.70 | 0.76 | 0.77 | 0.44 |
| Depreciation And Amortization In Income Statement | 0.70 | 0.76 | 0.77 | 0.44 |
| Amortization | 0.70 | 0.76 | 0.77 | 0.44 |
| Amortization Of Intangibles Income Statement | 0.70 | 0.76 | 0.77 | 0.44 |
| Operating Revenue | 267.84 | 321.48 | 348.88 | 418.63 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MiMedx Group, Inc.this co. | MDXG | $458M | 9.64 | 1.78 | 18.9% | 4.00 |
| agilon health, inc. | AGL | $465M | - | 3.65 | -308.8% | -0.53 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $464M | - | 0.86 | -61.5% | -1.69 |
| Varex Imaging Corporation | VREX | $462M | - | 0.97 | -14.4% | 7.73 |
| Orthofix Medical Inc. | OFIX | $461M | - |
| 1.02 |
| -20.5% |
| -94.86 |
| 4D Molecular Therapeutics, Inc. | FDMT | $461M | - | 1.00 | -27.7% | -0.45 |
| Pacific Biosciences of California, Inc. | PACB | $456M | - | 81.67 | -10214.5% | -5.12 |
| Candel Therapeutics, Inc. | CADL | $453M | - | 6.53 | -73.5% | -8.07 |
| Larimar Therapeutics, Inc. | LRMR | $451M | - | 4.62 | -212.2% | -1.85 |
| Peer Median | - | - | 2.33 | -67.5% | -1.77 | |